Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
265.9
-3.05 (-1.13%)
Market Cap: 34.30 Bil
Enterprise Value: 33.17 Bil
PE Ratio: 0
PB Ratio: 1,063.60
GF Score: 78/100 Alnylam Pharmaceuticals Inc at UBS Global Healthcare Conference Transcript
May 25, 2022 / 02:00PM GMT
Release Date Price:
$126.75
(-0.24%)
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst
Good morning, everyone. Thank you so much for joining us for day 3 of the UBS Healthcare Conference. Very happy to have Alnylam Pharmaceuticals here with us. By way of introduction, I'm Ellie Merle. I'm one of the biotech analysts here at UBS. Very happy to have Alnylam with us for a fireside chat. Joining us from Alnylam is Pushkal Garg, Chief Medical Officer.
And with that, thanks for joining us.
Questions & Answers
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst
And maybe before we dive into lots of fun APOLLO-B questions, high level, maybe can you frame the Alnylam pipeline and strategy and where you see the company in 3, 5 years from now?
Pushkal Garg
Alnylam Pharmaceuticals, Inc. - Chief Medical Officer and Executive VP of Development & Medical Affairs
Absolutely. Well, thank you, Ellie, for having us here, and thanks to UBS for inviting us to the conference. I'm happy to be here and to see so
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot